Variant
FLT3 ITD & D835(V/Y/F/H)
CI-VAR-00002041Explore in graph →CIViC 3209
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26438511
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia2 | ||||||||
| FLT3 ITD & D835(V/Y/F/H) | (oncogenic) | Oncogenic | C | Supports Oncogenicity | 3 | submitted | EID9141Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD) mutation is an aggressive hematologic malignancy with a grave prognosis. Targeted deep sequencing was performed on FLT3… (full text at CIViC) PMID 26438511 · Garg et al., 2015 · Open in CIViC | civic |
| FLT3 ITD & D835(V/Y/F/H) | Ponatinib | Predictive | D | Supports Resistance | 4 | submitted | EID8894Proliferation of Ba/F3 cells with FLT3 double mutations was studied for the activity of ponatinib. Compared to control cells with native FLT3-ITD mutant (IC50: 3.0nM), cells with double mutants, FLT3-… (full text at CIViC) PMID 23430109 · Smith et al., 2013 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available